Physicists from the Universities of Bayreuth and Grenoble have discovered a new mechanism of cell mobility. Their findings ...

According to analysts at BMO Capital Markets, non-obstructive hypertrophic cardiomyopathy would have meant a $1.3 billion ...

Bristol Myers Squibb BMY suffered a setback in the late-stage ODYSSEY-HCM study evaluating cardiovascular drug Camzyos ...

The kinetic cycle of myosin-driven movement consists of four basic steps. First, the myosin catalytic head binds ATP, which releases the head from actin. Second, ATP hydrolysis results in a ...

Bristol Myers Squibb announced that mavacamten did not achieve statistical significance in meeting the dual primary endpoints ...

No biological system has been studied by more diverse approaches than the actin-based molecular motor myosin. Biophysics, biochemistry, physiology, classical genetics and molecular genetics have ...

BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

The randomized, double-blind, placebo-controlled ODYSSEY-HCM trial included 580 adult patients with symptomatic nonobstructive HCM.

In the developing brain, neurons must navigate through complex and often crowded tissue to reach their final ...

Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) ...